Ignite Creation Date:
2024-05-06 @ 1:44 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01884623
Status:
COMPLETED
Last Update Posted:
2024-02-09
First Post:
2013-06-18
Brief Title:
Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent andor Metastatic Squamous Cell Head and Neck Cancer
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Study Overview
Official Title:
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent andor Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ELAN-UNFIT
Brief Summary:
To test whether cetuximab improves efficacytolerance as compared to methotrexate in first line treatment of unfit patients ³ 70 years old with recurrent and or metastatic HNSCC Efficacy assessed by failure free survival
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 20121937 | OTHER | CSET number | None |